Healthcare Industry News: antiviral
News Release - January 23, 2008
Carol L. Brosgart, M.D., Appointed to the Board of Directors of Juvaris BioTherapeutics, Inc.PLEASANTON, Calif., Jan. 23 (HSMN NewsFeed) -- Juvaris BioTherapeutics, Inc., a private company, today announced the appointment of Carol L. Brosgart, M.D. as a member of Juvaris' Board of Directors, effective immediately. In commenting on this appointment, Martin D. Cleary Co-Founder, Chairman and CEO of Juvaris said, "We welcome Carol to our Board of Directors. Her extensive clinical experience and relevant biotechnology industry success will be especially useful to our team in building the company."
For the past 10 years Dr. Brosgart has been involved in the development of antiviral therapies at Gilead Sciences, Inc., a biotechnology company in Foster City, CA dedicated to advancing therapeutics against life-threatening diseases worldwide. She currently serves as Vice President, Public Health and Policy. Prior to this she served as Vice President, Medical Affairs and Vice President, Clinical Research. Before joining Gilead Sciences, Dr. Brosgart spent more than 20 years in public health, clinical medicine and clinical research at the Alameda County Health Care Services Agency, Oakland, California and at Alta Bates Medical Center in Berkeley, California. She was one of the first physicians in the United States caring for patients with HIV/AIDS and was the founder and Medical Director of the East Bay AIDS Center. While in practice, she was an active member of the clinical faculty of the School of Medicine at the University of California (San Francisco and Berkeley). Carol received her B.S. degree from the University of California, Berkeley and her M.D. degree from the University of California, San Francisco. Her residency training in pediatrics and preventive medicine was conducted at the University of California (San Francisco and Berkeley) and the State of California.
In commenting on the appointment, Dr. Brosgart said, "Effective, global immunization programs have eradicated or minimized the impact of many infectious diseases, but emerging new diseases continue to provide the scientific and biomedical community with new challenges. I look forward to working with the Juvaris team and with their collaborators as they continue their efforts to bring novel approaches to vaccine and adjuvant development."
Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.
When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs.
The Company recently completed a Series A financing with Kleiner Perkins Caufield & Byers as the sole investor. It plans to start up to four clinical studies in 2008. The first will be a prophylactic vaccine for Influenza A, the second a therapy for chronic Hepatitis B, the third for chronic Hepatitis C and a fourth for Acute Myelogenous Leukemia (AML).
The Company encourages partnering inquiries and can be reached at its website at: http://www.juvaris.com.
Source: Juvaris BioTherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.